VP Regional Commercial Leader (Biotech CDSD)- US, Central Region
Thermo Fisher Scientific- Full Time
- Senior (5 to 8 years)
Employment Type:
Location Type:
Salary: $190,000 - $215,000 (Pay may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.)
Corcept is a leader in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). We have discovered over 1,000 proprietary cortisol modulators and received FDA approval for Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Our team is dedicated to advancing the possibilities of cortisol modulation to treat serious diseases, with over 30 ongoing studies across various disease areas including endocrinology, oncology, metabolism, and neurology.
The Region Manager will lead a team of Clinical Specialists (CS) and provide consistent direction for the execution of sales and marketing strategies within their assigned region.
Applicants must be currently authorized to work in the United States on a full-time basis.
Corcept is an Equal Opportunity Employer. We appreciate the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information, and for an explanation of your rights and choices regarding your personal information, please refer to our Privacy Notice.
Website: https://www.corcept.com/
Important Note: Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview process. Please be vigilant in checking that communication is in fact coming from Corcept, even when third-party tools are used for job advertising.
#LI-Remote
Develops cortisol modulators for medical conditions
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.